Frequency of severe acute toxicity events (SATE), overall/by individual SATE type, among women receiving adjuvant trastuzumab-based treatment for HER2-positive, early invasive breast cancer, by age at diagnosis (ordered by most frequently recorded; only individual SATE with >5% presented). Here, ERBB2 is linked to invasive breast carcinoma.